Basic Information:
Vortioxetine hydrobromide is a novel bisaryl thioalkylamine antidepressant co-developed by Takeda Japan and Lingbei, Denmark. It is used in the treatment of depression and anxiety disorders. In September 2013, it was awarded the United States. The FDA approved the listing for the treatment of major depressive disorders in adults. In October of the same year, vodisidinetin's marketing authorization application (MAA) received a positive opinion from the European Medicines Agency (EMA) Human Medicine Products Committee (CHMP), 2013 In December of this year, the EMA European Commission granted wattacetin to its sales rights throughout the EU. There are four specifications for vortioxetine: 5 mg, 10 mg, 15 mg, and 20 mg.

Valticetine hydrobromide is considered to be a novel multi-model antidepressant drug. In vitro studies have shown that it can antagonize 5-HT3, 5-HT7, and 5-HT1D receptors, activate 5-HT1A receptors, and partially activate 5- HT1B receptors, and inhibit 5-HT transport.

Vortioxetine is another antidepressant drug that was developed to replace the patent expired drug citalopram.

Application:

Vortioxetine is another antidepressant drug that was developed to replace the patent expired drug citalopram.